| Patient | Gilda Radner |
|---|---|
| Date of birth | 1946-06-28 |
| Identifiers | MRN HR-ML026-SYN-TD; SSN (made up) 000-26-8821 |
| Document date | 1986-04-14 |
| Author | Delia Marchand, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Biopsy result and gynecologic oncology consultation. [S]
Ms. Radner returns eight days after her first visit. The transvaginal ultrasound the next day showed solid and cystic masses in both ovaries with ascites; CT of the chest, abdomen and pelvis the day after that showed omental and peritoneal disease without spread to the liver, lungs or lymph nodes; and an ultrasound-guided core biopsy of the omentum two days later shows high-grade serous carcinoma of Mullerian origin. Dr. Varghese of gynecologic oncology saw her this morning. The bloating and early fullness are the same; she is eating small meals and has had no vomiting, and her bowels move every day. She says she is frightened but relieved to have an answer within a week. She had genetic counseling this afternoon. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Diagnosis | High-grade serous carcinoma of both ovaries with omental and peritoneal spread; clinical FIGO stage IIIC |
| Imaging | Ultrasound: bilateral complex masses, ascites. CT: omental caking, a right diaphragm nodule, no liver, lung or nodal disease |
| Symptoms | Bloating and early fullness unchanged; no vomiting or bowel obstruction |
| Coordination | Gynecologic oncology seen today; surgery planned in one week; genetic counseling done |
| Her questions | Whether surgery can remove it all, and what the genetic test means for her family |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; no fever or night sweats; weight steady |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Positive | Bloating and early fullness; no vomiting; bowels open daily |
| Genitourinary | Positive | Passing urine more often; no bleeding |
| Cardiovascular | Negative | No leg swelling or calf pain |
| Psychiatric | Positive | Frightened and tearful at times; PHQ-9 7 and GAD-7 8; no thoughts of self-harm |
6 systems reviewed. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1986-04-14 | Body height | 160 | cm | S |
| 1986-04-14 | Body weight | 58.9 | kg | S |
| 1986-04-14 | Body mass index (BMI) [Ratio] | 23 | kg/m2 | S |
| 1986-04-14 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1986-04-14 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1986-04-14 | Heart rate | 96 | /min | S |
| 1986-04-14 | Respiratory rate | 16 | /min | S |
| 1986-04-14 | Body temperature | 36.8 | Cel | S |
| 1986-04-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1986-04-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 1986-04-14 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | {score} | S |
Vital signs recorded on 1986-04-14; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Tired but composed; weight 58.9 kg; blood pressure 122/78, pulse 96 |
| Abdomen | Distended with shifting dullness; firm fullness in the upper abdomen consistent with the omental disease; non-tender; biopsy site clean |
| Pelvic | Examined with Dr. Varghese: fixed, irregular masses in both adnexa, larger on the right; cervix normal; no nodularity of the rectovaginal septum |
| Lymph nodes | No supraclavicular, axillary or inguinal nodes |
| Extremities | No leg swelling |
| Psychiatric | Anxious, tearful briefly, organized; humor intact |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Persistent bloating with tightness of her clothes, feeling full after a few bites, a dull lower abdominal and pelvic ache, and passing urine more often, on most days for about four weeks, in a woman of 39: the ovarian cancer symptom index is positive. Examination: a distended abdomen with shifting dullness and a firm, fixed, irregular mass in the right adnexa. Suspected ovarian cancer; transvaginal ultrasound, CT, CA-125 and gynecologic oncology review booked within the week | resolved | confirmed | R19.00 | S — Synthetic presenting problem linked to her documented abdominal symptoms; superseded by the diagnosis at the gynecologic oncology consultation. |
| High-grade serous carcinoma of both ovaries (Mullerian origin), diagnosed by image-guided omental core biopsy (PAX8 and WT1 positive, p53 aberrant), with bilateral adnexal masses, ascites, omental and diaphragmatic disease on CT: clinical FIGO stage IIIC; synthetic modern detail linked to her documented ovarian cancer | active | confirmed | C56.3 | S — Synthetic histology and stage; the documented diagnosis was stage IV ovarian cancer (D). |
| Peritoneal and omental metastases of the ovarian cancer, with ascites | active | confirmed | C78.6 | S — Synthetic extent of disease on CT and biopsy. |
| Family history of ovarian cancer in three relatives (her grandmother, an aunt, and a cousin) in a woman of Ashkenazi Jewish ancestry; no genetic testing in the family is known | active | confirmed | Z80.41 | S — Synthetic coding of her documented family history; the basis for genetic counseling. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Ovarian cancer symptom index | At presentation | Up to date | Positive at the first visit: bloating, early fullness and pelvic pain on most days for about four weeks |
| Imaging | Transvaginal ultrasound | At presentation with a pelvic mass | Up to date | Done the day after the first visit: bilateral solid and cystic adnexal masses with blood flow and ascites (O-RADS 5) |
| Imaging | CT of the chest, abdomen and pelvis with contrast | Before primary treatment | Up to date | Omental caking, a 1.2 cm right diaphragm nodule and pelvic peritoneal nodules; no liver, lung or lymph node disease; no pleural effusion |
| Laboratory | Tissue diagnosis | Before treatment, by biopsy or at surgery | Up to date | Omental core biopsy: high-grade serous carcinoma, PAX8 and WT1 positive, p53 aberrant |
| Laboratory | CA-125 and CEA | At diagnosis | Up to date | CA-125 1240 U/mL and CEA 1.6 ng/mL at the first visit; the ratio points to an ovarian rather than a bowel primary |
| Laboratory | Blood count, kidney and liver function before surgery | Within 30 days before surgery | Up to date | From the first visit: hemoglobin 12.4 g/dL, platelets 412, creatinine 0.72 mg/dL, albumin 3.6 g/dL |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before chemotherapy | Ordered | Hepatitis B surface antigen, core antibody and surface antibody, hepatitis C antibody, and HIV drawn today |
| Referral | Genetic counseling | At diagnosis of epithelial ovarian cancer | Completed today | Pedigree taken and consent given |
| Laboratory | Germline multigene panel | Once, at diagnosis, for every woman with epithelial ovarian cancer | Ordered | BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 and the Lynch syndrome genes; result in about three weeks |
| Laboratory | Tumor testing for BRCA1 and BRCA2 and homologous recombination deficiency | On the surgical specimen, before the maintenance decision | Due | To be sent from the operation next week |
| Referral | Gynecologic oncology | Before any surgery for suspected ovarian cancer | Completed today | Seen this morning; recommendations in the consultation note |
| Medication safety | Thromboprophylaxis after cancer surgery | From surgery for four weeks | Due | Enoxaparin 40 mg daily for 28 days planned after the operation |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, at each treatment phase, and when symptoms change | Completed today | PHQ-9 7 and GAD-7 8, mild, with fear about the diagnosis; no thoughts of self-harm |
| Self-management | Psychosocial support and information | At diagnosis and throughout | Completed today | Plain explanation of the diagnosis and plan with written information; she chose who would be told; details of a cancer support community group given |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 4.2026 (2026); Konstantinopoulos PA, et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol 2020;38(11):1222-1245 (2020); Goff BA, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007;109(2):221-227 (2007); Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk (2017); Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (2023); Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020 (2020); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Surgery in one week with Dr. Varghese. Primary care review three weeks after surgery, on the first chemotherapy day, with the pathology and genetic results. Call for vomiting, inability to eat, breathlessness, or leg swelling. Next scheduled visit 1986-05-12: review three weeks after cytoreductive surgery: pathology, genetic results, and the first cycle of chemotherapy. [S]